Muszbek N - Search Results

1

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.

Carr BI, Carroll S, Muszbek N, Gondek K. Carr BI, et al. Among authors: muszbek n. J Gastroenterol Hepatol. 2010 Nov;25(11):1739-46. doi: 10.1111/j.1440-1746.2010.06404.x. J Gastroenterol Hepatol. 2010. PMID: 21039835 Review.

2

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.

Muszbek N, Shah S, Carroll S, McDonald H, Dale P, Maroun J, Knox J. Muszbek N, et al. Curr Med Res Opin. 2008 Dec;24(12):3559-69. doi: 10.1185/03007990802563706. Curr Med Res Opin. 2008. PMID: 19032137 Clinical Trial.

3

Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.

Muszbek N, Remak E, Evans R, Brennan VK, Colaone F, Shergill S, Mullan D, Ross PJ. Muszbek N, et al. Future Oncol. 2021 Mar;17(9):1055-1068. doi: 10.2217/fon-2020-1004. Epub 2020 Nov 23. Future Oncol. 2021. PMID: 33222542

4

Modelling survival in hepatocellular carcinoma.

Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak J, Ross P. Muszbek N, et al. Curr Med Res Opin. 2012 Jul;28(7):1141-53. doi: 10.1185/03007995.2012.691422. Epub 2012 Jun 26. Curr Med Res Opin. 2012. PMID: 22563794

5

Overview of parametric survival analysis for health-economic applications.

Ishak KJ, Kreif N, Benedict A, Muszbek N. Ishak KJ, et al. Among authors: muszbek n. Pharmacoeconomics. 2013 Aug;31(8):663-75. doi: 10.1007/s40273-013-0064-3. Pharmacoeconomics. 2013. PMID: 23673905 Review.

6

Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC).

Muszbek N, Evans R, Remak E, Brennan VK, Colaone F, Shergill S, Ross P, Mullan D. Muszbek N, et al. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):147-154. doi: 10.1080/14737167.2021.1973892. Epub 2021 Sep 6. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 34488517

7

The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review.

Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. Muszbek N, et al. Int J Clin Pract. 2008 Feb;62(2):338-51. doi: 10.1111/j.1742-1241.2007.01683.x. Int J Clin Pract. 2008. PMID: 18199282 Free PMC article. Review.

8

The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.

Muszbek N, Kadambi A, Lanitis T, Hatswell AJ, Patel D, Wang L, Singer JW, Pettengell R. Muszbek N, et al. Clin Ther. 2016 Mar;38(3):503-15. doi: 10.1016/j.clinthera.2016.01.004. Epub 2016 Feb 5. Clin Ther. 2016. PMID: 26856929 Free article. Clinical Trial.

9

Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.

Hawkins N, Muszbek N, Evans R, Dequen-O'Byrne P, Jones T, McNamara L. Hawkins N, et al. Among authors: muszbek n. J Comp Eff Res. 2022 Aug;11(11):805-813. doi: 10.2217/cer-2022-0070. Epub 2022 Jun 9. J Comp Eff Res. 2022. PMID: 35678206 Free article. Clinical Trial.

10

The Life and Death of the End of Life Treatment Appraisal Criteria in Nice Technology Appraisals?

Kiss Z, Muszbek N, Benedict A. Kiss Z, et al. Among authors: muszbek n. Value Health. 2014 Nov;17(7):A661. doi: 10.1016/j.jval.2014.08.2427. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202408 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters